Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis

Clinical and Experimental Rheumatology

Volumn 23, Issue 4, 2005, Pages 438-446

  Chintalacharuvu, Subba ^a   Evans, Glenn F ^a   Shih, Chuan ^a   Bryant, Henry U ^a   Sandusky, George E ^a   Zuckerman, Steven H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Anti folates; Inflammation; Macrophage inflammatory protein 1; Tumor necrosis factor

Indexed keywords

2',5' THIENYL 5,10 DIDEAZATETRAHYDROFOLIC ACID; CYTOKINE; HYPOXANTHINE; LIPOPOLYSACCHARIDE; LY 309886; LY 329201; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHOTREXATE; MONOKINE; N [[5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; PURINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; EX VIVO STUDY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; RAT; SPLEEN WEIGHT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; ENZYME INHIBITORS; GLUTAMIC ACID; HINDLIMB; LIPOPOLYSACCHARIDES; MACROPHAGE INFLAMMATORY PROTEIN-1; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, INBRED LEW; TETRAHYDROFOLATES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 26844549171     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. CAPERELLI CA, GIROUX EL: The human glycinamide ribonucleotide transformylase domain: Purification, characterization, and kinetic mechanism. Arch Biochem Biophys 1997; 341: 98-103.
2. SANGHANI SP, MORAN RG: Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase. Biochemistry 1997; 36: 10506-16.
3. ZHANG Y, DESHARNAIS J, GREASLEY SE, BEARDSLEY GP, BOGER DL, WILSON IA: Crystal structures of human GAR Tfase at low and high pH and with substrate β-GAR. Biochemistry 2002; 41: 14206-15.
4. WARREN L, BUCHANAN JM: Biosynthesis of the purines. XIX. 2-Amino-N-ribosylacetamide 5′-phosphate (glycinamide ribotide) transformylase. J Biol Chem 1957; 229: 613-26.
5. MORAN RG, BALDWIN SW, TAYLOR EC, SHIH C: The 6S and 6R-diastereomers of 5,10-dideaza-5,6,7,8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem 1989; 264: 21047-51.
6. HABECK LL, LEITNER TA, SHACKELFORD KA et al.: A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res 1994; 54: 1021-6.
7. MENDELSOHN LG, SHIH C, SCHULTZ RM, WORZALLA JF: Biochemistry and pharmacology of glycinamide ribonucleotide forymlytransferase inhibitors: LY309887 and lometrexol. Invest New Drugs 1996; 14: 287-94.
8. McLEOD HL, CASSIDY J, POWRIE RH et al.: Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide forymlytransferase inhibitor AG2034. Clin Cancer Res 2000; 6: 2677-84.
9. McGUIRE JJ: Anticancer antifolates: Current status and future directions. Curr Pharm Des 2003; 9: 2593-613.
10. WEINBLATT ME, COBLYN JS, FOX DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
11. CRONSTEIN BN, EBERLE MA, GRUBER HE, LEVIN RI: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991; 88: 2441-5.
12. MORABITO L, MONTESINOS MC, SCHREIBMAN DM et al.: Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101: 295-300.
13. CHAN ESL, CRONSTEIN BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 266-73.
14. JOHNSON WJ, MARTINO MJ, MEUNIER PC, MUIRHEAD KA, HANNA N: Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol 1988; 15: 745-9.
15. KAWAI S, NAGAI K, NISHIDA S, SAKYO K, MURAI E, MIZUSHIMA Y: Low-dose pulse methotrexate inhibits articular destruction of adjuvant arthritis in rats. J Pharm Pharmacol 1997; 49: 213-5.
16. BAGGOTT JE, MORGAN SL, KOOPMAN WJ: The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. Arthritis Rheum 1998; 41: 1407-10.
17. NAGAYOSHI R, NAKAMURA M, IJIRI K, YOSHIDA H, KOMIYA S, MATSUYAMA T: LY309887, antifolate via the folate receptor suppresses marine type II collagen-induced arthritis. Clin Exp Rheumatol 2003; 21: 719-25.
18. BENSLAY DN, BENDELE AM: Development of a rapid screen for detecting and differentiating immunomodulatory vs anti-inflammatory compounds in rats. Agents Actions 1991: 34: 254-6.
19. LU X, ERRINGTON J, CHEN VJ, CURTIN NJ. BODDY AV, NEWELL DR: Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 2000; 5: 271-7.
20. GRIFFITH DA, JARVIS SM: Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996; 1286: 153-81.
21. GANGJEE A, DUBASH NP, ZENG Y, McGUIRE JJ: Recent advances in the chemistry and biology of folypoly-γ-glutamate synthetase substrates and inhibitors. Curr Med Chem Anti -Canc Agents 2002; 2: 331-55.
22. ULRICH CM, ROBIEN K, SPARKS R: Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenomics 2002; 3: 299-313.
23. CHEN VJ, BEWLEY JR, ANDIS SL et al.: Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998; 78 (Suppl. 3): 27-34.
24. KUNKEL SL, LUCACS N, KASAMA T, STRIETER RM: The role of chemokines in inflammatory joint disease. J Leukoc Biol 1996; 59: 6-12.
25. LIPSKY PE, Van der HEIJDE DMFM, St. CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti tumor necrosis factor trial in Rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343: 1594-602.
26. FIRESTEIN GS: Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
27. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
28. MORGAN SL, BAGGOTT JE, BERNREUTER WK, GAY RE, ARANI R, ALARCON GS: MTX affects inflammation and tissue destruction differently in the rat AA model. J Rheumatol 2001; 28: 1476-81.
29. BAGGOTT JE, MORGAN SL, HA TS, ALARCON GS, KOOPMAN WJ, KRUMDIECK CL: Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 1993; 11 (Suppl. 8): 101-5.
30. MONTESINOS MC, DESAI A, DELANO D et al.: Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003; 48: 240-7.
31. SZABO C, SCOTT GS, VIRAG L et al.: Suppression of macrophage inflammatory protein (MIP)-1a production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998; 125: 379-87.
32. HERRMANN ML, SCHLEYERBACH R, KIRSCHBAUM BJ: Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacol 2000; 47: 273-89.
33. CUTOLO M, SULLI A, GHIORZO P, PIZZORNI C, CRAVIOTTO C, VILLAGGIO B: Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 297-302.
34. HO CY, WONG CK, LI EK, TAM LS, LAM CWK: Suppressive effect of combination treatment of leflunomide and methotrexate on chemokines expression in patients with rheumatoid arthritis. Clin Exp Immunol 2003; 133: 132-8.
35. SCHORLEMMER HU, SCHLEYERBACH, R: Derivatives of leflunomide's active metabolite A77-1726, the malononitrilamides (MNAs), prevent the development of experimental arthritis. Int J Immunother 1998; 14: 177-84.
36. BENDELE A, McCOMB J, GOULD T et al.: Animal models of arthritis; Relevance to human disease. Toxicol Pathol 1999; 27: 134-42.
37. O'DELL JR: Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350: 2591-602.
38. WOODS A, HOBSON P, KLAVINSKIS LS: Recent developments in molecular therapeutic approaches for rheumatoid arthritis. Curr Opin Mol Ther 2004; 6: 395-402.